




FIG. 1

Chr/Clx/MASP-1/MASP-2/MASP-3




FIG. 2A





FIG. 2B



3
G^x
—
L




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B

12/90




FIG. 8C




FIG. 9

Binding of AbD Ab #40 & #60 to rat MASP2 polypeptides




FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13




FIG. 14A




FIG. 14B





FIG. 15



**p=0.0035

FIG. 16





FIG. 17

 $\rho = 0.0174$




FIG. 19





FIG. 20

Sirius red staining of kidneys harvested 7 days after UUO



*p=0.0477

FIG. 21

Hydroxy proline content in kidneys harvested 7 days after UUO





FIG. 22

30/90



252




FIG. 24

32/90





FIG. 25



*p=0.035

FIG. 26

Macrophage infiltration - Proteinuria correlation
(Wild Type)




FIG. 27A




FIG. 27B




FIG. 28





FIG. 29






FIG. 31

40/90

Pathological changes H&E staining




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39

Urine albumin/creatinine ratio (uACR) in IgAN patients treated with OMS646




FIG. 40

49/90




FIG. 41A

50/90




FIG. 41B

51/90




FIG. 41C

52/90



FIG. 41D




FIG. 42A




FIG. 42B




FIG. 43




FIG. 44




FIG. 45




FIG. 46

59/90




FIG. 47B



FIG. 47A




FIG. 48




FIG. 49




FIG. 50




FIG. 51A




FIG. 51B




FIG. 52A




FIG. 52B




FIG. 52C




FIG. 52D




FIG. 52E

70/90




FIG. 53

71/90




FIG. 54

72/90




FIG. 55

73/90




FIG. 56

74/90




FIG. 57

75/90




FIG. 58

76/90




FIG. 59

77/90




FIG. 60

78/90




FIG. 61




FIG. 62

MASP2/C1Inh complex assay, calibrating
Using pooled acute Covid-19 plasma




FIG. 63






FIG. 64








FIG. 67





FIG. 68



Narsoplimab treated




FIG. 70B

Narsoplimab treated




FIG. 70A




FIG. 71




FIG. 72B

FIG. 72A

90/90




FIG. 73